Evolocumab in Primary Prevention of Cardiovascular Events
Introduction to Evolocumab Trials
- The FOURIER trial demonstrated a 15% reduction in primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for angina, or revascularization) and 20% reduction in cardiovascular death, MI, or stroke over 2.2 years in patients with prior ASCVD, according to the American Diabetes Association 3
- The ODYSSEY OUTCOMES trial showed a 1.6% absolute risk reduction over 2.8 years in patients with recent acute coronary syndrome, as reported by the American Heart Association 1
Current Guideline Restrictions
- Guidelines from the American College of Cardiology consistently restrict PCSK9 inhibitors to secondary prevention or familial hypercholesterolemia, noting the absence of primary prevention data, with a strength of evidence level of A 1
- The American Diabetes Association recommends that PCSK9 inhibitors are reserved for secondary prevention or familial hypercholesterolemia, with a moderate strength of evidence 6
- In primary prevention populations (except familial hypercholesterolemia), the number needed to treat would be prohibitively high, according to the American Heart Association, with a low strength of evidence 6
Implications for Current Practice
- Until VESALIUS-CV results are published, evolocumab should NOT be used in patients without prior MI or stroke, except for familial hypercholesterolemia, as recommended by the American College of Cardiology, with a high strength of evidence 6
- Ezetimibe should always be tried before evolocumab due to lower cost and established safety, according to the American Diabetes Association, with a moderate strength of evidence 6
- For heterozygous familial hypercholesterolemia patients age 30-75 years with LDL-C ≥100 mg/dL despite maximally tolerated statin plus ezetimibe, evolocumab may be considered, as reported by the American Heart Association, with a low strength of evidence 6